Although OS in this study is immature and requires further validation, we suggest that both pembrolizumab plus chemotherapy and monotherapy are valid options with similar efficacy in TFS for patients with advanced NSCLC exhibiting a high PD-L1 TPS. The gene discussed is CD274; the disease is non-small cell lung carcinoma.